北陆药业(300016)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300016 北陆药业

已收盘 11-15 15:00:00

{"stockData":{"symbol":"300016","market":"SZ","secType":"STK","nameCN":"北陆药业","latestPrice":6.87,"timestamp":1731654210000,"preClose":7.04,"halted":0,"volume":13266150,"delay":0,"floatShares":491000000,"shares":492000000,"eps":-0.1003,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.17,"latestTime":"11-15 15:00:00","open":7.02,"high":7.16,"low":6.86,"amount":93097400,"amplitude":0.0426,"askPrice":6.88,"askSize":424,"bidPrice":6.87,"bidSize":1107,"shortable":0,"etf":0,"ttmEps":-0.1003,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1731893400000},"adr":0,"adjPreClose":7.04,"symbolType":"stock","openAndCloseTimeList":[[1731634200000,1731641400000],[1731646800000,1731654000000]],"highLimit":7.74,"lowLimit":6.34,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":491935176,"pbRate":2.21,"roa":"--","roe":"1.47%","epsLYR":-0.15,"committee":0.451993,"marketValue":3380000000,"floatMarketCap":3374000000,"peRate":-68.494517,"changeRate":-0.0241,"turnoverRate":0.027,"status":1},"requestUrl":"/m/hq/s/300016","defaultTab":"news","newsList":[{"id":"2483694025","title":"北陆药业（300016）11月13日主力资金净卖出3400.13万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483694025","media":"证券之星","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483694025?lang=zh_cn&edition=full","pubTime":"2024-11-13 15:27","pubTimestamp":1731482839,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年11月13日收盘，北陆药业报收于7.41元，下跌3.64%，换手率4.86%，成交量23.87万手，成交额1.77亿元。11月13日的资金流向数据方面，主力资金净流出3400.13万元，占总成交额19.23%，游资资金净流入339.13万元，占总成交额1.92%，散户资金净流入3061.0万元，占总成交额17.31%。北陆药业主营业务：对比剂制剂及原料药、中枢神经类和降糖类药品的研发、生产与销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111300019802.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0042","BK0046","BK0239","300016"],"gpt_icon":0},{"id":"2482722336","title":"北陆药业：公司对比剂生产线通过欧盟GMP认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2482722336","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482722336?lang=zh_cn&edition=full","pubTime":"2024-11-12 16:34","pubTimestamp":1731400494,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0060","BK0042","BK0046","BK0239","300016"],"gpt_icon":0},{"id":"2482272141","title":"北陆药业(300016.SZ)：对比剂生产线通过欧盟GMP认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2482272141","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482272141?lang=zh_cn&edition=full","pubTime":"2024-11-12 16:14","pubTimestamp":1731399265,"startTime":"0","endTime":"0","summary":"智通财经APP讯，北陆药业(300016.SZ)发布公告，近期，公司收到荷兰药监局依据欧洲药品管理局相关法规颁发的《药品GMP证书》，认证产线：终端灭菌注射剂生产线。根据欧盟成员国之间的GMP互认制度，通过GMP认证表明本次接受认证的对比剂生产线已符合欧盟GMP标准，为公司对比剂产品向欧盟等规范市场出口创造了条件，有利于公司进一步推进海外市场的拓展，提升公司对比剂产品的国际市场竞争力，未来将对公司经营产生积极影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1209770.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300016","BK0042","BK0239","BK0060","BK0046"],"gpt_icon":0},{"id":"2481396794","title":"专栏节选：日本九州参访的新体验--今周刊“老谢开讲”","url":"https://stock-news.laohu8.com/highlight/detail?id=2481396794","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481396794?lang=zh_cn&edition=full","pubTime":"2024-11-07 08:00","pubTimestamp":1730937600,"startTime":"0","endTime":"0","summary":"专栏节选：日本九州参访的新体验--今周刊“老谢开讲”本文由台湾《今周刊》杂志提供，节选自11月7日出版的当期“老谢开讲”专栏在美国总统大选揭晓前夕，我率了一组五十余人的考察团到日本九州，实地勘查台积电到熊本设厂的现况，也顺便看了周边供电系统。这趟行程中，正好遇上日本众议院选举，地方街头有很多候选人的看板。在福冈，我们参访的第一家公司是九州电力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nL4T3MD1AX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0060","300016","BK0046","BK0042","BK0239"],"gpt_icon":0},{"id":"2480118443","title":"【机构调研记录】中海基金调研松炀资源、北陆药业等3只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2480118443","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480118443?lang=zh_cn&edition=full","pubTime":"2024-11-04 08:01","pubTimestamp":1730678488,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及11月1日披露的机构调研信息，中海基金近期对3家上市公司进行了调研，相关名单如下：1）松炀资源 个股亮点：公司主要从事环保再生纸的研发、生产和销售，是一家集废纸回收、环保造纸及涂布成型于一体；公司地处汕头市，从事环保再生纸的研发、生产及销售，有望受益于大湾区的发展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110400001439.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0042","BK0060","603863","300016","BK0239","BK0222"],"gpt_icon":0},{"id":"2480388278","title":"华安证券：给予北陆药业增持评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2480388278","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480388278?lang=zh_cn&edition=full","pubTime":"2024-11-03 07:45","pubTimestamp":1730591121,"startTime":"0","endTime":"0","summary":"华安证券股份有限公司谭国超,李昌幸,刘洪飞近期对北陆药业进行研究并发布了研究报告《利润超预期增长，战略转型初见成效》，本报告对北陆药业给出增持评级，当前股价为7.16元。　　公司已通过并购的方式收购承德天原药业80%的股权，并已成功并表。控股子公司海昌药业碘克沙醇化学原料药获批上市，生产车间通过GMP符合性检查。最新盈利预测明细如下：该股最近90天内共有1家机构给出评级，增持评级1家。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110300000166.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300016","600909"],"gpt_icon":0},{"id":"2480024006","title":"北陆药业：关于公司非独立董事辞职的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2480024006","media":"新浪财经-鹰眼工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480024006?lang=zh_cn&edition=full","pubTime":"2024-11-01 18:21","pubTimestamp":1730456460,"startTime":"0","endTime":"0","summary":"北京北陆药业股份有限公司关于公司非独立董事辞职的公告本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。北京北陆药业股份有限公司董事会于近日收到公司董事王福龙先生提交的辞职信，王福龙先生因个人原因申请辞去公司第八届董事会董事、审计委员会委员职务，辞职后仍在公司担任其他职务。北京北陆药业股份有限公司 董事会二○二四年十一月一日","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/ggzz/2024-11-01/doc-incuqfsw6318982.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2024-11-01/doc-incuqfsw6318982.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","300016","BK0060","BK0046","BK0042"],"gpt_icon":0},{"id":"2480027060","title":"北陆药业（300016）11月1日主力资金净卖出6843.74万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2480027060","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480027060?lang=zh_cn&edition=full","pubTime":"2024-11-01 15:26","pubTimestamp":1730446006,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年11月1日收盘，北陆药业报收于7.16元，下跌9.25%，换手率8.56%，成交量42.05万手，成交额3.1亿元。北陆药业主营业务：对比剂制剂及原料药、中枢神经类和降糖类药品的研发、生产与销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110100023177.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0060","300016","BK0042","BK0239"],"gpt_icon":0},{"id":"2479240709","title":"北陆药业：平安医药、开源证券等多家机构于10月31日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2479240709","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479240709?lang=zh_cn&edition=full","pubTime":"2024-10-31 18:52","pubTimestamp":1730371945,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年10月31日北陆药业发布公告称平安医药臧文清 叶寅 韩盟盟、开源证券阮帅、中海基金姚晨曦、浙江英睿资管王俊杰、中信建投基金杨经华、中邮证券鲁春娥、霄沣投资尹霄羽、上海人寿吕国启、华夏基金张帆、贵源投资赖正健、上海雪石资管吴曦、深圳翼虎投资熊斌、颢升私募基金夏敬慧、金百镕投资马学进、中金公司柳天慧、合晟资管陆志锋、青岛城投城金集团郎需谦、中天汇富基金慕陶于2024年10月31日调研我司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103100038264.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK1161","BK0042","09939","BK0060","BK0239","161027","BK1574","300016","159938","BK0046"],"gpt_icon":0},{"id":"2479770586","title":"北陆药业最新公告：公司通过巴西国家卫生监督局GMP认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2479770586","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479770586?lang=zh_cn&edition=full","pubTime":"2024-10-31 17:41","pubTimestamp":1730367680,"startTime":"0","endTime":"0","summary":"北陆药业公告，公司近期通过了巴西国家卫生监督局（巴西ANVISA）的GMP（药品生产质量管理规范）认证。这为公司对比剂产品成功进入巴西市场创造了条件，对公司进一步拓展巴西市场和其他国际市场有积极作用。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103100037287.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","BK0042","300016","BK0046"],"gpt_icon":0},{"id":"2479277783","title":"北陆药业(300016.SZ)通过巴西国家卫生监督局GMP认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2479277783","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479277783?lang=zh_cn&edition=full","pubTime":"2024-10-31 17:38","pubTimestamp":1730367526,"startTime":"0","endTime":"0","summary":"智通财经APP讯，北陆药业(300016.SZ)发布公告，近期，公司通过了巴西国家卫生监督局(“巴西ANVISA”)的GMP(药品生产质量管理规范)认证。本次顺利通过巴西ANVISAGMP认证，为公司对比剂产品成功进入巴西市场创造了条件，对公司进一步拓展巴西市场和其他国际市场有着非常积极的作用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1204953.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0046","300016","BK0042","BK0239","BK0060"],"gpt_icon":0},{"id":"2479756634","title":"北陆药业(300016.SZ)发布前三季度业绩，净利润2439.43万元，增长1156.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479756634","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479756634?lang=zh_cn&edition=full","pubTime":"2024-10-29 17:50","pubTimestamp":1730195444,"startTime":"0","endTime":"0","summary":"智通财经APP讯，北陆药业(300016.SZ)发布2024年三季度报告，该公司前三季度营业收入为7.3亿元，同比增长12.30%。归属于上市公司股东的净利润为2439.43万元，同比增长1156.34%。归属于上市公司股东的扣除非经常性损益的净利润为2521.87万元，同比增长275.59%。基本每股收益为0.0497元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1202512.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300016"],"gpt_icon":0},{"id":"2479473378","title":"北陆药业最新公告：前三季度净利润同比增长1156%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479473378","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479473378?lang=zh_cn&edition=full","pubTime":"2024-10-29 17:33","pubTimestamp":1730194437,"startTime":"0","endTime":"0","summary":"北陆药业披露三季报，公司前三季度实现营业收入7.3亿元，同比增长12.3%；净利润2439.43万元，同比增长1156.34%；基本每股收益0.05元。报告期内，公司继续推动纳入集采的对比剂产品及降糖类产品的集采执标工作，并积极推广其他未纳入集采的产品销售，同时海外市场业务进展顺利，公司营业收入持续稳定增长进而带动净利润相关指标较上年同期上涨。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102900032289.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300016"],"gpt_icon":0},{"id":"2479784914","title":"图解北陆药业三季报：第三季度单季净利润同比增163.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479784914","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479784914?lang=zh_cn&edition=full","pubTime":"2024-10-29 17:31","pubTimestamp":1730194306,"startTime":"0","endTime":"0","summary":"证券之星消息，北陆药业2024年三季报显示，公司主营收入7.3亿元，同比上升12.3%；归母净利润2439.43万元，同比上升1156.34%；扣非净利润2521.87万元，同比上升275.59%；其中2024年第三季度，公司单季度主营收入2.56亿元，同比上升20.77%；单季度归母净利润485.31万元，同比上升163.36%；单季度扣非净利润610.47万元，同比上升145.62%；负债率38.62%，投资收益574.6万元，财务费用3991.0万元，毛利率50.04%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102900032190.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300016"],"gpt_icon":0},{"id":"2477835442","title":"北陆药业最新公告：钆喷酸葡胺注射液通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2477835442","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477835442?lang=zh_cn&edition=full","pubTime":"2024-10-21 16:53","pubTimestamp":1729500804,"startTime":"0","endTime":"0","summary":"北陆药业公告，钆喷酸葡胺注射液通过仿制药质量和疗效一致性评价。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102100020257.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300016","BK0060","BK0239","BK0046","BK0042"],"gpt_icon":0},{"id":"2477288213","title":"北陆药业(300016.SZ)：钆喷酸葡胺注射液通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2477288213","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477288213?lang=zh_cn&edition=full","pubTime":"2024-10-21 15:48","pubTimestamp":1729496915,"startTime":"0","endTime":"0","summary":"智通财经APP讯，北陆药业 发布公告，近日，公司收到国家药品监督管理局核准签发的规格分别为10ml：4.69g、12ml：5.63g的钆喷酸葡胺注射液《药品补充申请批准通知书》，钆喷酸葡胺注射液通过仿制药质量和疗效一致性评价。米内网数据显示，2023年中国公立医疗机构终端钆喷酸葡胺注射液销售额超过8亿元，同比增长8.19%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1196668.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0060","BK0042","300016","BK0239","BK0046"],"gpt_icon":0},{"id":"2474956667","title":"北陆药业最新公告：控股子公司通过GMP符合性检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2474956667","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474956667?lang=zh_cn&edition=full","pubTime":"2024-10-10 16:16","pubTimestamp":1728548187,"startTime":"0","endTime":"0","summary":"北陆药业公告，控股子公司海昌药业的碘克沙醇原料药合成三车间、合成四车间及精烘包车间通过浙江省药品监督管理局的GMP符合性检查。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024101000027238.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","BK0042","300016","BK0046"],"gpt_icon":0},{"id":"2474527760","title":"北陆药业(300016.SZ)：海昌药业通过药品GMP符合性检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2474527760","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474527760?lang=zh_cn&edition=full","pubTime":"2024-10-10 15:46","pubTimestamp":1728546369,"startTime":"0","endTime":"0","summary":"智通财经APP讯，北陆药业(300016.SZ)公告，公司控股子公司浙江海昌药业股份有限公司(简称“海昌药业”)原料药(碘克沙醇)合成三车间、合成四车间、精烘包车间，生产线2通过GMP符合性检查。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1192273.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0046","300016","BK0060","BK0042","BK0239"],"gpt_icon":0},{"id":"2473350417","title":"北陆药业(300016.SZ)： 硫酸钠化学原料药获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2473350417","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473350417?lang=zh_cn&edition=full","pubTime":"2024-10-08 16:24","pubTimestamp":1728375850,"startTime":"0","endTime":"0","summary":"智通财经APP讯，北陆药业(300016.SZ)公告，公司收到国家药品监督管理局核准签发的硫酸钠化学原料药上市申请批准通知书。公告显示，硫酸钠为容积性泻药，可促进排便反射或使排便顺利。硫酸钠不易被肠壁吸收而又易溶于水，在肠内形成高渗盐溶液，因此可保持大量水分在肠内，使肠内容积增大，对肠黏膜产生刺激，引起肠管蠕动而加速排便。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1190942.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300016","BK0060","BK0046","BK0042"],"gpt_icon":0},{"id":"2470702202","title":"北陆药业（300016）9月26日主力资金净买入1446.21万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2470702202","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470702202?lang=zh_cn&edition=full","pubTime":"2024-09-26 15:21","pubTimestamp":1727335311,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年9月26日收盘，北陆药业报收于5.38元，上涨5.91%，换手率4.69%，成交量23.04万手，成交额1.22亿元。9月26日的资金流向数据方面，主力资金净流入1446.21万元，占总成交额11.86%，游资资金净流入959.83万元，占总成交额7.87%，散户资金净流出2406.03万元，占总成交额19.73%。北陆药业主营业务：对比剂制剂及原料药、中枢神经类和降糖类药品的研发、生产与销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024092600017133.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300016","BK0239","BK0060","BK0042"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2009-10-30","address":"北京市密云区水源西路3号","stockEarnings":[{"period":"1week","weight":-0.0852},{"period":"1month","weight":0.1081},{"period":"3month","weight":0.4312},{"period":"6month","weight":0.3471},{"period":"1year","weight":-0.1135},{"period":"ytd","weight":-0.0351}],"companyName":"北京北陆药业股份有限公司","boardCode":"AI0027","perCapita":"16446股","boardName":"医药制造业","registeredCapital":"49193万元","compareEarnings":[{"period":"1week","weight":-0.0352},{"period":"1month","weight":0.0399},{"period":"3month","weight":0.1567},{"period":"6month","weight":0.056},{"period":"1year","weight":0.0917},{"period":"ytd","weight":0.1196}],"survey":"　　北京北陆药业股份有限公司的主营业务为对比剂制剂及原料药、中枢神经类和降糖类药品的研发、生产与销售。公司的主要产品为钆喷酸葡胺注射液、钆布醇注射液、钆贝葡胺注射液、碘海醇注射液、碘帕醇注射液、碘克沙醇注射液、格列美脲片、瑞格列奈片、九味镇心颗粒、钆喷酸葡胺及辅料、钆布醇及辅料、碘海醇、碘佛醇、碘克沙醇、碘普罗胺及碘帕醇。公司是我国对比剂行业的市场领先者。因药物警戒工作表现突出，公司已连续7年获得“药品不良反应日常监测工作先进单位”荣誉称号。","serverTime":1731791667799,"listedPrice":17.86,"stockholders":"29865人(较上一季度增加4.69%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"北陆药业(300016)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供北陆药业(300016)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"北陆药业,300016,北陆药业股票,北陆药业股票老虎,北陆药业股票老虎国际,北陆药业行情,北陆药业股票行情,北陆药业股价,北陆药业股市,北陆药业股票价格,北陆药业股票交易,北陆药业股票购买,北陆药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"北陆药业(300016)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供北陆药业(300016)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}